Anixa Biosciences Inc (ANIX) SEC Filing 8-K Material Event for the period ending Monday, March 22, 2021

Anixa Biosciences Inc

CIK: 715446 Ticker: ANIX

View differences made from one to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anixa Biosciences Inc.


Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits

Ticker: ANIX
CIK: 715446
Form Type: 8-K Corporate News
Accession Number: 0001493152-21-006721
Submitted to the SEC: Wed Mar 24 2021 4:28:50 PM EST
Accepted by the SEC: Wed Mar 24 2021
Period: Monday, March 22, 2021
Industry: Medical Laboratories
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: